Iovance (NASDAQ: IOVA) CMO reports RSU vesting and tax share withholding

Rhea-AI Filing Summary

IOVANCE BIOTHERAPEUTICS, INC. Chief Medical Officer Friedrich Graf Finckenstein reported equity compensation activity involving restricted stock units (RSUs) and common shares. On March 5, 2026, 31,246 RSUs vested, each converting into one share of common stock at a stated price of $0.00 per share.

Following the RSU vesting and conversion, 16,520 common shares were withheld by the company at $4.58 per share to satisfy mandatory tax withholding requirements, which the disclosure specifies is not an open market sale. After these transactions, Graf Finckenstein directly owned 131,957 shares of common stock and 62,504 RSUs from this grant, with the remaining RSUs scheduled to vest in equal quarterly installments.

Insider Trade Summary

31,246 shares exercised/converted

Mixed 3 txns

Insider GRAF FINCKENSTEIN FRIEDRICH

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	31,246	$0.00	--
Exercise	Common Stock	31,246	$0.00	--
Tax Withholding	Common Stock	16,520	$4.58	$76K

Holdings After Transaction: Restricted Stock Units — 62,504 shares (Direct); Common Stock — 148,477 shares (Direct)

Footnotes (1)

1. Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. Represents the common stock remaining after deducting the common stock withheld for taxes. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The remaining RSUs will vest in equal quarterly installments. Such aggregate number reflects the remainder of such RSUs granted on March 5, 2025, but does not include any other RSUs held by such Reporting Person.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GRAF FINCKENSTEIN FRIEDRICH

(Last) (First) (Middle)

C/O IOVANCE BIOTHERAPEUTICS, INC.

825 INDUSTRIAL ROAD, SUITE 100

(Street)

SAN CARLOS CA 94070

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IOVANCE BIOTHERAPEUTICS, INC. [ IOVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	03/05/2026		M		31,246	A	$0	148,477	D
Common Stock(2)	03/05/2026		F		16,520	D	$4.58	131,957(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(4)	03/05/2026		M			31,246	(5)	(5)	Common stock	31,246	$0.00	62,504(6)	D

Explanation of Responses:

1. Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date.

2. Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities.

3. Represents the common stock remaining after deducting the common stock withheld for taxes.

4. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

5. The remaining RSUs will vest in equal quarterly installments.

6. Such aggregate number reflects the remainder of such RSUs granted on March 5, 2025, but does not include any other RSUs held by such Reporting Person.

	/s/ Friedrich Graf Finckenstein	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did IOVA Chief Medical Officer report?

IOVANCE BIOTHERAPEUTICS, INC. (IOVA) Chief Medical Officer Friedrich Graf Finckenstein reported RSU vesting and related share activity. 31,246 RSUs vested and converted to common shares, with some shares withheld by the company to cover mandatory tax obligations tied to this vesting event.

How many IOVA restricted stock units vested for the Chief Medical Officer?

The Chief Medical Officer had 31,246 restricted stock units vest, each representing a right to receive one share of common stock. These RSUs converted into the same number of common shares, reflecting routine equity compensation, rather than an open market purchase of additional shares.

Were any IOVA shares sold on the open market in this insider report?

No open market sales were reported. 16,520 common shares were withheld by the company at $4.58 per share solely to satisfy tax withholding obligations upon RSU vesting. The disclosure explicitly states this withholding is not an open market sale of securities.

How many IOVA shares does the Chief Medical Officer own after these transactions?

After the reported transactions, the Chief Medical Officer directly owned 131,957 shares of IOVANCE common stock. This figure reflects the RSU conversion into common shares, minus the portion withheld by the company to cover related tax obligations on the vesting event.

What RSU balance remains for the IOVA Chief Medical Officer after vesting?

After this vesting event, the disclosure shows 62,504 RSUs remaining from the March 5, 2025 grant. These remaining RSUs are scheduled to vest in equal quarterly installments, continuing the executive’s equity-based compensation over time under the existing grant terms.

How were the tax obligations handled for the IOVA RSU vesting?

Tax obligations were met through share withholding. The company retained 16,520 common shares at $4.58 per share to satisfy mandatory tax withholding due at vesting. This method avoids a separate market sale, as specified in the disclosure footnotes.